+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Amyotrophic Lateral Sclerosis - Global Strategic Business Report

  • PDF Icon

    Report

  • 183 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309395
The global market for Amyotrophic Lateral Sclerosis was estimated at US$1.0 Billion in 2023 and is projected to reach US$3.6 Billion by 2030, growing at a CAGR of 19.4% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord. This condition leads to the gradual degeneration and death of motor neurons, which are essential for controlling voluntary muscles. As these neurons deteriorate, patients experience muscle weakness, twitching, and eventually, the loss of the ability to initiate and control muscle movement. This leads to severe physical impairments, including difficulties in speaking, swallowing, and breathing. Despite the varying progression rates among individuals, ALS invariably leads to paralysis and is ultimately fatal, with the majority of patients succumbing to respiratory failure within three to five years from the onset of symptoms. Understanding the nature of ALS is crucial for developing effective treatments and providing comprehensive care for those affected.

How Are Research and Treatments Evolving for ALS?

Research into ALS is rapidly advancing, with numerous studies focusing on understanding its underlying mechanisms and developing potential treatments. Genetic research has identified several gene mutations associated with familial ALS, providing insights into its hereditary forms and opening avenues for targeted therapies. The development of biomarkers is another critical area, aiming to improve diagnosis, monitor disease progression, and evaluate treatment efficacy. Currently, only a few medications, such as Riluzole and Edaravone, are approved for ALS, offering modest benefits in slowing disease progression. However, ongoing clinical trials are exploring various approaches, including gene therapy, stem cell therapy, and the use of neuroprotective agents. Advances in technology are also facilitating innovative treatment modalities, such as brain-computer interfaces that help ALS patients communicate and control devices using their brain signals. These evolving research and treatment strategies are essential for improving the quality of life and prognosis for ALS patients.

What Challenges and Opportunities Exist in Managing ALS?

Managing ALS presents significant challenges, given the rapid progression and severe impact of the disease. Multidisciplinary care, involving neurologists, physical therapists, speech therapists, and other healthcare professionals, is vital for addressing the complex needs of ALS patients. Access to specialized care centers and support services can enhance disease management, but geographical and financial barriers often limit this access. Additionally, the emotional and psychological burden on patients and caregivers is substantial, necessitating comprehensive support systems. Despite these challenges, there are opportunities for improving care through technological innovations, such as telemedicine and assistive devices, which can provide remote support and enhance patient independence. Advocacy and awareness initiatives are also crucial for securing funding for research and improving public understanding of ALS, ultimately contributing to better patient outcomes and support networks.

What is Driving Market Growth for ALS Treatments?

The growth in the Amyotrophic Lateral Sclerosis (ALS) market is driven by several factors, including advancements in medical research, increasing awareness of the disease, and the development of innovative treatment approaches. Technological advancements, such as the identification of genetic markers and the use of advanced imaging techniques, are enhancing the understanding and diagnosis of ALS. The rise in funding for ALS research from both governmental and non-governmental organizations is spurring the development of new therapies and clinical trials. The growing demand for effective treatments is also driven by an aging population, as the incidence of ALS increases with age. Additionally, the expansion of patient advocacy groups and awareness campaigns is leading to earlier diagnosis and better access to care, further propelling market growth. Pharmaceutical companies are increasingly investing in the development of novel therapies, including gene therapies and neuroprotective agents, which hold promise for altering the course of the disease. These factors collectively are sustaining the momentum in the ALS treatment market, offering hope for improved management and potential cures in the future.

Regional Analysis

Gain insights into the U.S. market, which was estimated at $285.8 Million in 2023, and China, forecasted to grow at an impressive 18.4% CAGR to reach $534.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Amyotrophic Lateral Sclerosis Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Amyotrophic Lateral Sclerosis Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Amyotrophic Lateral Sclerosis Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AB Science SA, Apotex, Inc., Aquestive, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 23 Featured):

  • AB Science SA
  • Apotex, Inc.
  • Aquestive
  • Biogen, Inc.
  • Brainstorm Cell Therapeutics Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • Genervon Biopharmaceuticals LLC
  • Ionis Pharmaceuticals, Inc.
  • Kringle Pharma Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Neuralstem, Inc.
  • Orion Corporation
  • Orphazyme A/S
  • Sanofi SA
  • Treeway BV
  • Valeant Pharmaceuticals International, Inc.
  • ViroMed Co., Ltd.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Amyotrophic Lateral Sclerosis - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Incidence of ALS Drives Adoption of Multidisciplinary Care Approaches
  • Increasing Genetic Research Throws the Spotlight On ALS Understanding
  • Advancements in Biomarkers Propel Growth in ALS Diagnosis and Treatment
  • Development of Gene Therapies Expands Addressable Market Opportunity
  • Innovations in Stem Cell Research Strengthen Business Case for ALS Treatments
  • Innovations in Brain-Computer Interfaces Enhance Patient Communication
  • Advances in Neuroprotective Agents Accelerate Demand for New ALS Therapies
  • Aging Population Expands Market Opportunity for ALS Treatments
  • Advances in Imaging Techniques Propel Growth in ALS Diagnostic Accuracy
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Amyotrophic Lateral Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Amyotrophic Lateral Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Amyotrophic Lateral Sclerosis Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 5: USA Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 6: USA Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
CANADA
  • TABLE 7: Canada Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 8: Canada Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
JAPAN
  • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 9: Japan Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 10: Japan Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
CHINA
  • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 11: China Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 12: China Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
EUROPE
  • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 13: Europe Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 14: Europe Historic Review for Amyotrophic Lateral Sclerosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 15: Europe 16-Year Perspective for Amyotrophic Lateral Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
FRANCE
  • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 16: France Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 17: France Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
GERMANY
  • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 18: Germany Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 19: Germany Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
ITALY
  • TABLE 20: Italy Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Italy Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
UNITED KINGDOM
  • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 22: UK Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 23: UK Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
REST OF EUROPE
  • TABLE 24: Rest of Europe Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 25: Rest of Europe Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
ASIA-PACIFIC
  • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 26: Asia-Pacific Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Asia-Pacific Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
REST OF WORLD
  • TABLE 28: Rest of World Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 29: Rest of World Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AB Science SA
  • Apotex, Inc.
  • Aquestive
  • Biogen, Inc.
  • Brainstorm Cell Therapeutics Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • Genervon Biopharmaceuticals LLC
  • Ionis Pharmaceuticals, Inc.
  • Kringle Pharma Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Neuralstem, Inc.
  • Orion Corporation
  • Orphazyme A/S
  • Sanofi SA
  • Treeway BV
  • Valeant Pharmaceuticals International, Inc.
  • ViroMed Co., Ltd.

Table Information